Programmable RNA immunotherapies for solid tumors.
We use RNA to turn tumors into targets the immune system can recognize and attack. iOncologi is a clinical-stage biotechnology company based in Gainesville, Florida.
Clinical stage
Phase I ongoing in glioblastoma, with more programs advancing toward the clinic
Foundational U.S. patent
RNA-based immunotherapy, exclusively licensed from the University of Florida Research Foundation
Published in Nature
Findings in Nature and Nature Biomedical Engineering support the approach
AI partnership
Working with SandboxAQ, an Alphabet spinout, to optimize antigens for glioblastoma
Three platforms, five programs.
Each platform is a different biological entry point into the same idea: use RNA to help the immune system recognize and attack solid tumors.
IONC101 / IONC102
Multilamellar RNA nanocomplex
RNA delivered in layered lipid particles to prime a broad immune response against tumor antigens. IONC102 pairs the platform with AI-optimized, off-the-shelf antigens, starting in glioblastoma.
Phase I ongoing in glioblastoma
IONC201 / IONC202
UNIFYR
Off-the-shelf mRNA designed to prime the immune system so more patients respond to checkpoint inhibitors. No tumor biopsy or sequencing is needed to make it.
Phase II/III planned
TAR001
Tumor-targeted nanoparticles
RNA nanoparticles targeted to EGFR-expressing tumor cells, designed to kill tumor cells directly and activate the immune system.
IND/CTA-ready; first-in-human planned
One idea behind them all: use RNA to turn tumors into targets the immune system can recognize and attack.
Patent-protected, peer-reviewed and partnered.
A foundational U.S. patent covers RNA-based formulations that enhance tumor responsiveness to immune checkpoint inhibitors. Published research supports the science behind it.
Why it matters. Findings published in Nature Biomedical Engineering and Nature link RNA-driven immune activation to improved survival among cancer patients receiving immune checkpoint inhibitor therapy. We are also working with SandboxAQ to apply AI to antigen optimization for glioblastoma.
Five programs, advancing toward the clinic.
A snapshot of where each program stands. The full pipeline has the detail.
Draft stage labels adapted from the October 2026 deck. Confirm before launch.
Built with leading institutions and technology partners.
Clinical partner
AI antigen optimization
An iOncologi subsidiary
Questions we hear most.
Can’t find what you need? Send us an inquiry and the team will follow up.
What does iOncologi do?
iOncologi is a clinical-stage biotechnology company developing RNA immunotherapies for solid tumors. Our programs use RNA to help the immune system recognize and attack tumors, and our programs grew out of research at the University of Florida.
How are the three platforms different?
They are three entry points into the same idea. The multilamellar RNA nanocomplex (IONC101 and IONC102) delivers RNA in layered lipid particles to prime a broad immune response. UNIFYR (IONC201 and IONC202) uses off-the-shelf mRNA to help more patients respond to checkpoint inhibitors. TAR001 uses tumor-targeted nanoparticles to deliver RNA to EGFR-expressing tumor cells.
What makes UNIFYR different?
UNIFYR is designed to be off the shelf. Because it does not depend on the tumor’s own sequence, it does not require a tumor biopsy to manufacture, and it is intended to apply across patients and across multiple solid tumor types.
How does iOncologi use AI?
Through a partnership with SandboxAQ, we are using AI to design and optimize antigens for IONC102, a glioblastoma program built on the same delivery platform as IONC101.
What is TargImmune?
TargImmune is an iOncologi subsidiary and the home of TAR001, our tumor-targeted RNA nanoparticle program.
Are your therapies approved?
No. iOncologi is a clinical-stage biotechnology company. Our therapies are investigational, and their safety and efficacy have not been established.
How can I learn more about iOncologi?
Submit the general inquiry form below with your name, organization and area of interest, and the team will follow up directly.
Let’s talk about what comes next.
Whether you partner or collaborate in research, tell us who you are and what you’d like to explore.
Thank you
Your inquiry has been received. The team will follow up directly.